[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595254":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":17,"responsibleParty":33,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":7,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":7,"maxAge":7,"enrollmentInfo":45,"targetDuration":48,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Xiangbin Pan, MD","CONTACT","88396655","panxiangbin@fuwaihospital.org",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":7},"Fengwen Zhang, MD","88396654",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Fuwai Hospital","RECRUITING","Beijing","100037","China","CN",{"type":26,"coordinates":27},"Point",[28,29],116.39723,39.9075,{"lat":29,"lon":28},[32],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Pan Xiangbin","Principle Investigator","100595254","echocardiography-guided-tavr-echo-tavr-100595254",false,"NCT07030062","Echocardiography Guided TAVR (Echo TAVR)","Transcatheter Aortic Valve Replacement With Echocardiography Guidance","Inclusion Criteria:\n\n1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, which is defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m\u002Fs, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2\u002Fm2);\n2. a history of malignancy or a high familial risk of cancer, with refusal to undergo contrast- or radiation-guided procedures;\n3. chronic kidney disease and refuse to receive contrast agents or radiation exposure.\n\nExclusion Criteria:\n\nRequired hybrid procedures or concomitant interventions on other cardiac malformations; Deemed inoperable due to extremely high surgical risk or severe comorbidities; Had untreated clinically significant coronary vascular disease amenable to revascularization; Previously undergone aortic valve replacement.","ALL",{"count":46,"type":47},20,"ESTIMATED","1 Month","OBSERVATIONAL","Conventional transcatheter aortic valve replacement (TAVR) relies on fluoroscopic and contrast agents. However, in high-risk patients, exposure to ionizing radiation and contrast agents is contraindicated and undesirable. Echocardiography guidance TAVR can offer a feasible and safer strategy for TAVR.",[52,53],"Transcatheter Aortic Valve Replacemen","Echocardiography","2025-06-12",{"date":56,"type":57},"2025-06-19","ACTUAL",{"date":59,"type":57},"2025-02-18",{"date":61,"type":47},"2025-12-31",{"name":35,"class":6},1]